A multi-centre, randomised, placebo-controlled, doubleblind, parallel-group trial to evaluate safety and efficacy of spesolimab [BI 655130] in adult patients with ulcerative pyoderma gangrenosum [PG] who require systemic therapy (NCT06624670)
Bi 1368-0140
The 1368-0140 study is designed to evaluate the safety and efficacy of Spesolimab in adult participants with ulcerative pyoderma gangrenosum (PG) who require systemic therapy.
The treatment period will be approximately 52 weeks and will be administered monthly via infusion.
Program & service
This trial is being run with the Specialty Medicine service, and as part of the Dermatology program.
Trial phase
Phase 3
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Professor Johannes S Kern
Key inclusion data
Are 18 years or older
Have been diagnosed with PG that requires systemic therapy
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTRIf you would like further details or have any questions about this clinical trial, we encourage you to get in touch with us and a member of our team will be happy to provide you with more information.